DealIncyclix Bio, a Research Triangle Park, Durham, NC-based biotech company, raised $11.25 million in a Series B fundraising round led by Eshelman Ventures with participation from Eli Lilly and Company, Cape Fear BioCapital, and others.
More on VC News Daily →
SERIES B
08/29/2025
Ambrosia Biosciences, a Boulder, CO-based oral GLP-1 therapeutics...
TeiaCare, a Milan-based healthcare technology company, raised €7 million...
ReAlta Life Sciences, a Norfolk, VA-based clinical-stage biotech, raised...
Ambient Clinical Analytics, a Rochester, MN-based real-time clinical...
Tubulis GmbH, a Munich-based clinical-stage ADC biotech, was acquired for...
Stipple Bio, a Cambridge, MA-based biotech therapeutics company, raised...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
